Establishment of KRAS G12C mutant patient-derived xenograft (PDX) models for pre-clinical evaluation of KRAS G12C targeted anticancer therapy.

被引：0
|
作者：
Shi, Wenting [1 ]
Tang, Xuzhen [2 ]
Zhang, Jingying [1 ]
Kuang, Xinhong [1 ]
Zhang, Yan [1 ]
Wang, Jingjing [1 ]
Gu, Qingyang [1 ]
Ji, Qunsheng [2 ]
机构：
[1] WuXi AppTec Suzhou Co Ltd, Suzhou, Peoples R China
[2] WuXi AppTec Shanghai Co Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3004
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers
    Khan, Husain Yar
    Nagasaka, Misako
    Li, Yiwei
    Aboukameel, Amro
    Uddin, Md. Hafiz
    Sexton, Rachel
    Bannoura, Sahar
    Mzannar, Yousef
    Al-Hallak, Mohammed Najeeb
    Kim, Steve
    Beydoun, Rafic
    Landesman, Yosef
    Mamdani, Hirva
    Uprety, Dipesh
    Philip, Philip A.
    Mohammad, Ramzi M.
    Shields, Anthony F.
    Azmi, Asfar S.
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (05): : 342 - 352
  • [32] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
    Pinto, L. Masfarre
    Rocha, P.
    Clave, S.
    Gorro, N. Navarro
    Sanchez, I.
    Giner, M.
    Lloret, A. Corbera
    Garcia, A. Taus
    Parreira, A. S. D. F. M.
    Paricio, B. Bellosillo
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
  • [33] In Response to "De Novo KRAS G12C Mutant SCLC: A Case Report"-
    Balbach, Meridith L.
    Eisenberg, Rosana
    Iams, Wade T.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (11):
  • [34] Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition
    Tsai, Yihsuan S.
    Woodcock, Mark G.
    Azam, Salma H.
    Thorne, Leigh B.
    Kanchi, Krishna L.
    Parker, Joel S.
    Vincent, Benjamin G.
    Pecot, Chad V.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (04):
  • [35] KRAS G12C mutant allele amplification drives resistance to sotorasib in vitro
    Mohn, Deanna
    Saiki, Anne Y.
    Achanta, Pragathi
    Stapper, Andres Plata
    Lipford, J. Russell
    Verma, Rati
    CANCER RESEARCH, 2023, 83 (07)
  • [36] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [37] Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
    Li, Ling
    Wu, Yinrong
    Yang, Zichao
    Xu, Chenglong
    Zhao, Huiting
    Liu, Jin
    Chen, Jingxuan
    Chen, Jianjun
    BIOORGANIC CHEMISTRY, 2021, 117
  • [38] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [39] Diverse alterations associated with resistance to KRAS(G12C) inhibition
    Yulei Zhao
    Yonina R. Murciano-Goroff
    Jenny Y. Xue
    Agnes Ang
    Jessica Lucas
    Trang T. Mai
    Arnaud F. Da Cruz Paula
    Anne Y. Saiki
    Deanna Mohn
    Pragathi Achanta
    Ann E. Sisk
    Kanika S. Arora
    Rohan S. Roy
    Dongsung Kim
    Chuanchuan Li
    Lee P. Lim
    Mark Li
    Amber Bahr
    Brian R. Loomis
    Elisa de Stanchina
    Jorge S. Reis-Filho
    Britta Weigelt
    Michael Berger
    Gregory Riely
    Kathryn C. Arbour
    J. Russell Lipford
    Bob T. Li
    Piro Lito
    Nature, 2021, 599 : 679 - 683
  • [40] The Research Progress of Direct KRAS G12C Mutation Inhibitors
    Yang, Ai
    Li, Min
    Fang, Mingzhi
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
12345